Micronutrients in Congestive Heart Failure: An Integrative Review

Jaclyn K Gaulden1*, Susan J Appel2 and Victoria Kilcawley3

1Anderson University, South Carolina, USA
2Capstone College of Nursing, The University of Alabama, USA
3Spartanburg Regional Healthcare System, South Carolina, USA

*Corresponding author: Jaclyn K Gaulden, DNP, NP-C, Anderson University, 23 Flintwood Drive, Simpsonville, Anderson, SC 29681, USA, E-mail: jgaulden@gmail.com

Congestive heart failure (CHF) is a common disabling disease that affects approximately 5.1 million people in the United States (US). More than 55,000 deaths annually are contributed to CHF [1,2]. CHF occurs equally among men and women and is responsible for approximately 11 million office visits per year [2]. Economic cost of CHF in 2010 was $39.2 billion and accounted for 5.4% of the total health care budget [3,4].

Hallmark pathology of CHF is cardiac dysfunction which leads to congested organs with hypoperfusion of tissues and may occur with or without preserved left ventricular (LV) ejection fraction [5,6]. Common symptoms of CHF include dyspnea, fatigue, and exertional intolerance as well as edema, an audible S3 gallop and rales in the lungs [7]. In short, CHF leads to disability, impaired health-related quality of life (HRQL), decreased exercise tolerance and ultimately death.

As a systemic illness CHF is affected by many factors including neurohormonal abnormalities, elevated levels of inflammation, oxidative stress, and micronutrient deficiencies. Micronutrients consist of vitamins and minerals needed for energy and normal body function. Several micronutrients also have antioxidant properties, reduce inflammation and may also be involved in neurohormonal signaling [3]. Micronutrient supplementation allows for the correction of deficiencies in critical myocyte pathways, including those associated with adenosine triphosphate production (ATP), protein production, intracellular calcium balance, and the reduction of oxidative stress [4].

Advanced age, frequent hospitalizations, anorexia, and malnutrition have all been linked to the increased risk of nutrition deficiencies in patients with CHF. Nutritional status is critical in patients with CHF due to the side effect of unintentional weight loss known as cachexia and decrease of micronutrients from diuretics [3,8-10]. Cachexia often complicates CHF and leads to low albumin as is often seen among patients with poor nutrition [11]. Social isolation among the elderly caused by reduced mobility can also lead to inadequate intake due to eating alone and difficulty preparing meals [9,10,12].

Treatment of CHF includes pharmacologic therapy such as beta-blockers, angiotensin receptor blockers, diuretics, angiotensin-converting enzymes inhibitors and nonpharmacologic therapy, which includes exercise training, implantable cardioverter-defibrillators, cardiac resynchronization therapy, and patient education. Both pharmacologic and nonpharmacologic treatments have shown to have beneficial outcomes and some improvement in mortality; however, hospitalizations for CHF continue to rise [4,9,13,14]. Additional interventions are needed to prevent progression and improve outcomes among patients living with CHF.

Methods

An integrative literature review was conducted using PRISM guidelines, databases were searched (e.g., PubMed, Cumulative Index to Nursing and Allied Health Literature (CINHAL), Cochran, and Google Scholar) for studies published within 2004-2014, that examined the role of micronutrients in patients with CHF. Combinations of the following search terms were used: CHF,
congestive heart failure, heart failure, micronutrients, nutrition, and B vitamins including thiamine, vitamin B$_{12}$, homocysteine, folate, vitamin D, magnesium, and coenzyme Q$_{10}$. Inclusion criteria were articles in English containing original research on participants with CHF aged ≥ 19. A total of N = 856 articles were examined with n = 21 meeting all criterion for inclusion within this review (see Figure 1).

**Results**

Studies included in this review are summarized within Table 1. Five studies examined the effects of coenzyme Q$_{10}$.
CoQ\textsubscript{10} supplementation in patients with CHF [7,15-18]. Five studies looked at the role of vitamin D deficiency and supplementation among patients with CHF [19-23]. Six studies examined the role of homocysteine as well as treatment with folate, vitamin B\textsubscript{6}, and vitamin B\textsubscript{12} [24-29]. In addition, two studies assessed thiamine deficiency and the effect of supplementation [10,30]. Two studies examined magnesium orotate supplementation in patients [14,31]. One study examined the role of micronutrients on quality of life and LV function [12]. The following sections discuss the different studies for the various micronutrients that play a role in the symptoms and overall cardiac function among patients living with CHF.

\textbf{CoQ\textsubscript{10}}

CoQ\textsubscript{10}, also known as ubiquinone, is a fat-soluble quinone and mitochondrial coenzyme, essential for ATP formation [15,16,32]. Studies support that CoQ\textsubscript{10} is necessary for adequate LV function [7,15-18]. CoQ\textsubscript{10} can improve cellular bioenergetics and has potential to prevent and treat CVD, including CHF by increasing LV function [15]. It is estimated that 25% of the required CoQ\textsubscript{10} is obtained from diet. The remaining 75% is produced within body cells [32,33]. Constant supply of CoQ\textsubscript{10} is necessary for adequate LV function. However, aging decreases endogenous synthesis of CoQ\textsubscript{10} [17,32].

A study by Molyneux, et al. [16] examined the association between CoQ\textsubscript{10} levels and increased mortality by following N = 236 patients with CHF. As 76 deaths occurred leading to a conclusion that low CoQ\textsubscript{10} levels increase mortality. The correlation between the CoQ\textsubscript{10} and mortality was found to be greater than that with plasma N-terminal peptide of B-type natriuretic peptide (NT-proBNP) suggesting that decreased levels of CoQ\textsubscript{10} are associated with increased mortality and LV function regardless of the initial severity of CHF [16].

A 5-year prospective randomized-controlled trial was conducted among elderly by Alehagen, Johansson, Björnstedt, Rosén, and Dahlström [17]. Patients were randomized to receive a combination pill of CoQ\textsubscript{10} 200 mg per day with selenium yeast 200 mcg per day (n = 124) or placebo (n = 104) for 48 months. They were monitored every 6th month for 5 years with clinical examinations of LV function. The researchers concluded a significant reduction in cardiovascular mortality was seen among the treatment group (p = 0.015). NT-proBNP levels were lower after supplementation (p = 0.014) as well an improved LV function (p = 0.03) [17].

Adarsh, Kaur, and Mohan [15] found that CoQ\textsubscript{10} had a significant impact on New York Heart Association (NYHA) classifications for CHF, quality of life, diastolic dysfunction, and dysrhythmias. They conducted a quasi-experimental study (N = 87) with hypertrophic cardiomyopathy. The treatment group received 100 mg of CoQ\textsubscript{10} twice daily and the control received conventional treatment. The treatment group had an improvement in: NYHA classification by ≥ 1 (p < 0.005), quality of life on 6 minute walk test (p < 0.005), diastolic function by ≥ 1 parameter (p < 0.005), and significant reduction in LVOT gradient ≥ 15 mmHg in obstructive CHF cases (p < 0.005). Among the treatment group, no patients suffered cardiac dysrhythmias in contrast to four patients in the control having ventricular tachycardia [15].

A randomized-controlled trial conducted by Fumagalli, et al. [7], found that total work capacity (TWC) was significantly improved in patients with stable CHF after treatment with CoQ\textsubscript{10} terclatrate (Q-ter) and creatine daily for two months. Patients (N = 67) were randomized to receive 320 mg of Q-ter and 340 mg of creatine daily or placebo for eight weeks. The treatment group had improved TWC (p = 0.04), with no change in the placebo (p = 0.06). Peak VO\textsubscript{2} increased in the treatment group (p = 0.003) with no significant change in placebo. They concluded that when Q-ter and creatine are added to conventional treatment, positive effects on physical performance occur [7].

Belardinelli, et al. [18] studied patients (N = 23) with a NYHA class II and III and stable CHF secondary to ischemic heart disease, by randomizing patients into three groups, who received four different treatments simultaneously that consisted of CoQ\textsubscript{10}, CoQ\textsubscript{10} plus exercise training, placebo, and placebo plus exercise training in this double-blind, placebo-controlled cross-over design with each phase lasting four weeks. Researchers concluded that CoQ\textsubscript{10} was without any adverse effects, could improve LV function, functional capacity, and endothelial function. CoQ\textsubscript{10} paired with exercise training resulted in higher levels of CoQ\textsubscript{10}, and reduced peak systolic wall thickening (p ≤ 0.001) [18].

Correction of CoQ\textsubscript{10} deficiencies with supplementation has resulted in decreased mortality, improvement in cardiac function, NYHA classification, improvement in quality of life, and total work capacity. No side effects were noted among the studies and all researchers concluded that CoQ\textsubscript{10} could safely be given to patients with CHF [7,15-18].

\textbf{Vitamin D}

Vitamin D deficiency is associated with CVD risk factors. Vitamin D deficiency has been linked to low sun exposure, obesity, hypertension, diabetes, CVD and even death [21,23]. Vitamin D deficiency is common among patients with CHF due to decreasing plasma renin activity (PRA) levels as it binds to the Vitamin D receptors and preventing renin transcription which is actively involved in CVD [23]. Deficiency of Vitamin D is seen in aging due to a decrease in skin synthesis, with poor exposure to the sun as well as an impairment of 7-dehydrocholesterol conversions to previtamin D. Among patients with CHF, Vitamin D deficiency occurred with those that had a higher NYHA classification, shorter 6-minute walk test, and increased BNP [19].
A retrospective review of CHF patients conducted by Ameri, et al. [19] over months having similar sunny hours. Among the patients, only 2.2% (n = 2) had an adequate laboratory value of vitamin D (25[OH] D above 75 nmol/L). Due to this high prevalence of vitamin D deficiency, a retrospective review of patients with no diagnosis of CHF was done (n = 31) for comparison. Vitamin D levels were consistently lower in the patients with CHF as opposed to the control [19]. Likewise, a study by Gotsman, et al. [21] concluded that vitamin D deficiency is associated with CHF. In this larger study, (N = 49,834) all members of a Health Maintenance Organization (HMO), aged ≥ 45 had vitamin D measured. Vitamin D levels among members with CHF were compared to the members without CHF. Patients with CHF had consistently lower levels than that of the control (p < 0.00001). Prevalence of vitamin D deficiency was greater among patients with CHF (p < 0.00001). During the follow up period, the mortality rate was 15.4% (n = 455/3009) among patients with CHF but, only 1.7% (n = 802/46,825) (p < 0.00001) among the control, leading to a conclusion that vitamin D deficiency is a predictor of overall mortality [21].

Pilz, et al. [22], demonstrated the negative impact of vitamin D deficiency on LV function in the LUCRIC study (N = 3299), in patients referred for cardiac angiography and NT-proBNP, 25(OH) D and 1, 25(OH) D was obtained the morning before coronary angiography. A significant correlation was also seen with impaired LV function and decreased vitamin D levels (p < 0.001) as well as with a higher NYHA classification. During the follow up period of 7.7 years, 760 died with 188 from sudden cardiac death (25%) and 116 from CHF (15%). Among the participants, more sudden cardiac and CHF deaths occurred between December and May (101 SCDs and 62 CHF deaths) which were the months that patients had the lowest vitamin D levels at baseline [22].

Multiple studies [19,21,22] have examined vitamin D levels in patients with CHF and concluded that a strong correlation is seen between poor LV function and vitamin D deficiency. It is important to determine if supplementation will improve overall cardiac function. Amin, et al. [20] sought to determine if vitamin D supplementation improves the severity of CHF. This study looked at patients (N = 100) with CHF that were on optimal medical treatment for at least three months. Those deficient in vitamin D were given supplements of vitamin D3 (cholecalciferol) 50,000 IU weekly for eight weeks followed by 50,000 IU monthly for two months. After treatment patients were reassessed and the mean concentration of vitamin D increased by 41.86 nmol/L and Parathyroid Hormone levels decreased by 36.73 ng/L. In addition, a decrease in NT-proBNP levels was noted (p < 0.001) and an improved NYHA classification (p < 0.001). Vitamin D supplementation improved the 6-minute walk test (p < 0.001) leading to the conclusion that supplementation decreases the severity of CHF and improves functional capacity [20].

Schroten, et al. [23] conducted a randomized-prospective trial (VitD-CHF trial) with stable patients (N = 99) diagnosed with CHF on optimal medical therapy. Patients were randomized to Vitamin D3 2,000 IU daily or control without placebo given for six weeks. Results showed in the treatment group an increase in 25(OH) D levels and 1,25(OH)2D levels by week 3 with lasting effects throughout the treatment period. At the end of the six week trial period, 52% of the treatment group had adequate vitamin D levels whereas only 4% demonstrated normal vitamin D levels in the control. The treatment group had a decrease in PRA levels at the end of the six week period compared to the control (p = 0.002) along with PRC (p = 0.020) and PTH (p = 0.004). They concluded that patients with CHF could safely be treated with supplemental vitamin D3 [23].

B-Vitamins

A deficiency of B-vitamins is common among patients with CHF and contributes to the decreased energy reserves. B-vitamins play an important role in cellular energy production; therefore a deficiency of B-vitamins may impair adenosine triphosphate (ATP) synthesis. Due to the diminished energy stores available for myocyte contraction and decreased LV function worsening of CHF is seen [13,34]. A positive correlation between increased plasma homocysteine (homocysteinemia) was linked to the risk of CHF. Homocysteinemia is marker of overall poor prognosis due to increased cytokine production in CHF [13,27,29]. Homocysteinemia is negatively correlated with levels of: Creatinine, folate, vitamin B12, and serum albumin [27]. A positive correlation was found between homocysteinemia and an increased risk of CHF among healthy people [13].

Rodríguez, et al. [27] evaluated the prevalence, significance, and prognosis of homocysteinemia in hospitalized patients (N = 337). In addition, n = 36 controls were used for comparison. Results indicated that CHF was related to homocysteinemia in contrast to controls without CHF (p = 0.005). Prevalence of CHF correlated with homocysteinemia by 30% when level was below the 15th percentile, 40% between the 15th and 50th percentile, and up to 48% above the 50th percentile [27].

Guéant-Rodriguez, et al. [26] evaluated (N = 709) for the association between homocysteinemia and LV dysfunction. Results showed that total homocysteinemia was higher in patients with CAD versus those without (p < 0.001) and higher homocysteinemia was seen in patients with NYHA classification III than II (p = 0.0009). An association was seen between increased homocysteinemia with decreased LV function (< 40%) (p < 0.0001) [26].

Gibelin, et al. [25] examined the impact of homocysteinemia in patients (N = 278) with CHF versus a controls. It was noted that mean homocysteine levels were high-
er in the CHF group versus the controls (p = 0.001). They concluded there is a correlation between NYHA classification and homocysteine levels as well as homocysteinemia is a predictor of mortality in CHF (p = 0.0003) [25]. Maurer, et al. [24] concluded that homocysteinemia is an important risk factor for cardiac events among CHF patients (N = 161). It was found that patients with the highest homocysteine levels (≥ 20 µmol/L) had the highest incidence of death (p < 0.035) [24].

Lee, et al. [28] sought to determine if supplementation with vitamin-B₁₂ had a positive effect on lowering homocysteine levels in patients with CVD by looking at patients (N = 42) with at least a 70% stenosis of a major coronary artery. Patients were randomized to one of five groups: Placebo, vitamin-B₁₂ 5 mg, vitamin-B₁₂ 10 mg, vitamin-B₁₂ 50 mg, or folic acid 5 mg with 0.25 mg vitamin-B₁₂ for 12 weeks. Homocysteine levels decreased significantly (32%) with 12-weeks of folic acid and vitamin-B₁₂ supplementation (p < 0.001). Vitamin-B₁₂ and placebo were not effective in lowering homocysteine [28].

Andersson, Edvinsson, and Edvinsson [29] conducted a study to determine if vitamin supplementation can normalize homocysteine levels in patients (N = 14) with CHF. The homocysteine levels decreased (p < 0.01). Therefore, it was concluded that vitamin supplementation with folate can lower homocysteine levels in patients with CHF [29].

Thiamine, a water-soluble B-complex vitamin, plays a multifactorial role in patients with CHF [10,35]. Thiamine acts as a vasodilator and improves LV function by reducing afterload and increasing diuresis. Thiamine deficiency can cause cardiac hypertrophy, dysrhythmias, and worsening CHF [10,35]. Humans cannot effectively store or produce thiamine and are therefore dependent on ingestion through supplements or food. Patients with CHF are often deficient in thiamine due to age and comorbid conditions. Dietary issues also contribute to thiamine deficiency with early satiety and cachexia as often seen in patients with CHF and the need for a low sodium diet [35].

Hanninen, Darling, Sole, Barr, and Keith [10] demonstrated how prevalent thiamine deficiency is for CHF patients. Among (N = 100) hospitalized CHF patients who were analyzed for a thiamine deficiency and compared with matched controls. Patients admitted with CHF were found to be more likely to have a thiamine deficiency than that of their controls with 33% having a deficiency (p = 0.007) with spironolactone use, lack of thiamine supplementation, and preserved renal function significantly relating to the deficiency. Fifty percent of patients with CHF were also malnourished [10].

In a randomized-controlled, cross over study, Schoenenberger, et al. [30] found that beneficial effects are seen in patients with CHF when given thiamine supplementation. Patients (n = 9) were randomized to receive thiamine 300 mg per day or placebo for 28 days. After 6 weeks, a wash-out period was done to eliminate carry-over effects before a second treatment period of 28 days was started in which the medication was reversed. After twenty-eight days of treatment LV function increased in the thiamine group from 29.5% to 32.8% (p = 0.024) with no improvement seen in the placebo. Improvement in functional status was seen on the 6-minute walk test when receiving thiamine [30].

### Magnesium

Magnesium (Mg) plays an important role in the heart by its role is electrophysiology of cardiomyocytes. Patients with CHF often have hypomagnesemia and/or intracellular magnesium depletion leading to increased rate of mortality. Hypomagnesemia negatively affects heart rate variability which is often reported in CHF and leads to shorter survival [31].

Almozino-Sarafian, et al. [31] examined the effect of Mg administration on heart rate variability (HRV) in normomagnesemic patients with systolic CHF. Patients (N = 32) were randomly assigned to receive Mg citrate 300 mg/day for 5 weeks and compared to controls without placebo. After 5 weeks of treatment, patients receiving the Mg citrate, had an increase in Mg levels (p < 0.001) than controls (p = 0.042). In contrast, the intracellular Mg rose in the treatment group (p = 0.025) while no statistically significant change occurred in the controls (p = 0.7). The treatment group had significantly increased HRV. The investigators concluded that supplementation increases serum Mg levels, intracellular Mg levels and HRV-CD and can be beneficial in patients with CHF [31].

Stepura & Martynow [14] evaluated supplemental magnesium orotate on clinical symptoms and mortality in patients with CHF. In this prospective, randomized-controlled study, patients (N = 79) were randomized to receive magnesium orotate 6000 mg for 1 month then 3000 mg for 11 months or placebo. One year survival rates in the treatment group were better compared to controls (p < 0.05). Clinical symptoms significantly improved in the treatment group while symptoms deteriorated among the controls (p < 0.001) leading to the conclusion that magnesium orotate can be used as additional therapy in patients with CHF and is beneficial by decreasing symptoms as well as increasing survival rate [14].

### Other Micronutrients

Many other micronutrients have shown promise in the treatment of CHF including vitamin-A, vitamin-C, vitamin-E, selenium, copper, magnesium, zinc, and L-carnitine [3,4]. Witte, et al. [12] conducted a randomized-trial using a two-by-two method to determine the effect of micronutrient supplementation in patients with CHF. Patients (N = 30) were randomized to receive capsules of high dose micronutrients including calcium, magnesium, zinc, copper, selenium, vitamin-A, thiamine, riboflavin,
vitamin-B₆, vitamin-B₁₂, folate, vitamin-C, vitamin-E, and CoQ₁₀ or placebo for nine months. The treatment group demonstrated an increase in LV function with no change in controls (p < 0.05). The treatment group had a significant improvement in quality of life score in contrast to a slight decrease in the placebo group (p < 0.05). The 6-minute walk test, NYHA classification, and cytokine levels remained unchanged in both the treatment and placebo groups. They concluded that micronutrient supplementation could positively impact cardiac function and quality of life in patients with CHF [12].

Discussion

Many studies have been conducted that concluded that patients with CHF are often deficient in micronutrients. A deficiency of micronutrients can cause decreased LV function, decreased quality of life, and increased symptoms contributing to a progression of CHF. However, a much smaller number of studies have conducted interventions with micronutrient supplementation. Studies have shown that patients with CHF can safely take micronutrient supplemenations and experience a beneficial effect. There is a great need to decrease mortality in patients with CHF since current treatments are not being fully successful.

CoQ₁₀ has been shown to decrease mortality from a cardiac cause, improve NYHA classification, improve quality of life, increased total work capacity, and increased LV ejection fraction [7,15-18]. Likewise, vitamin-D supplementation decreases cardiovascular related mortality, increases LV ejection fraction, improvement of NYHA classification, increase in physical performance, as well as decreased PRA and PRC [19-23]. In addition, homocysteinemia has been shown to negatively impact cardiovascular health. Supplementation with B-vitamins, particularly folate, has been linked to decreasing homocysteine levels and therefore reduce symptoms of CHF [24-29]. Thiamine can also improve functional status in patients living with CHF [10,30]. Magnesium plays a role in the electrophysiology of the heart and supplementation is beneficial in patients with CHF [14,31].

A limitation of this area of research is a majority of studies were very small with studies ranging from only nine patients to a whole HMO (N = 46,825). In addition, patients were not followed for an extended period of time with the longest being 7.7 years with a majority of studies being shorter than two years. This leaves room for additional larger and longer studies to be performed. Studies indicate that micronutrients not only help improve LV function but also increase quality of life when living with CHF.

References


